Hepatotoxicity induced by antifungal drugs itraconazole and fluconazole in rats: A comparative in vivo study

Human and Experimental Toxicology

Volumn 23, Issue 11, 2004, Pages 519-525

  Somchit, Nhareet ^a   Norshahida, A R ^a   Hasiah, A H ^a   Zuraini, A ^a   Sulaiman, M R ^a   Noordin, M M ^b  

^a Universiti Putra Malaysia   (Malaysia)

^b UNIVERSITY PUTRA MALAYSIA   (Malaysia)

Author keywords

Fluconazole; Hepatotoxicity; Itraconazole; Rats

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMINOTRANSFERASE; ANTIFUNGAL AGENT; FLUCONAZOLE; ITRACONAZOLE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ARTICLE; BILE DUCT HYPERPLASIA; BILIARY CIRRHOSIS; CHEMICAL ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG LIVER LEVEL; DRUG MECHANISM; ENZYME ACTIVITY; GIANT CELL GRANULOMA; IN VIVO STUDY; LIVER CELL DAMAGE; LIVER NECROSIS; LIVER TOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; STATISTICAL SIGNIFICANCE;

ALANINE TRANSAMINASE; ALKALINE PHOSPHATASE; ANIMALS; ANTIFUNGAL AGENTS; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUCONAZOLE; HEPATITIS, TOXIC; HEPATOCYTES; INJECTIONS, INTRAPERITONEAL; ITRACONAZOLE; LIVER; MALE; NECROSIS; ORGAN SIZE; RATS; RATS, SPRAGUE-DAWLEY;

ANIMALIA;

EID: 10344245013     PISSN: 09603271     EISSN: None     Source Type: Journal    
DOI: 10.1191/0960327104ht479oa     Document Type: Article

References (25)

1. Terrell CL. Antifungal agents. Part II. The azoles. Mayo Clin Proc 1999; 74(1): 78-100.
2. Zuckerman JM, Tunkel AR. Itraconazole: a new triazole antifungal agent. Infec Control Hosp Epidemiol 1994; 15: 397-410.
3. Bailey EM, Krakovsky DJ, Rybak MJ. The triazole antifungal agent: a review of itraconazole and fluconazole. Pharmacol Therapy 1990; 10: 146-53.
4. Haria M, Bryson HM, Goa KL. Itraconazole: A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infection. Drugs 1996; 51: 586-620.
5. Saag MS, Dismukes, WE. Azole antifungal agents: emphasis on new triazoles. Antimicro Agents Chem 1988; 32: 1-8.
6. Inman W, Kubota K, Pearce G. PEM report No. 7. Itraconazole. Pharmacoepidimiol Drug Safety 1993; 2: 424-43.
7. Restrepo A, Roobledo J, Gomez I. Itraconazole therapy in lymphagenic and cutaneous sporotrichosis. Arch Dermatol 1986; 122: 413-17.
8. Lavrijsen APM, Balmus KJ, Nugteren-Huying WM, Roldaan AC, Vant Wout JW, Stricker BHC. Hepatic injury associated with itraconazole. Lancet 1992; 340: 251-52.
9. Lavrijsen AP, Balmus KJ, Nugteren-Huying WM, Roldaan AC, van't Wout JW, Stricker BH. Liver damage during administration of itraconazole. Ned Tijdschr Geneeskd 1993; 137: 38-41.
10. Tucker RM, Haq Y, Denning DW, Stevens DA. Adverse events associated with itraconazole in 189 patients on chronic therapy. J Antimicrob Chemother 1990; 26: 561-66.
11. Hecht FM, Wheat J, Korzun AH, Hafner R, Skahan KJ, Larsen R, Limjoco MT, Simpson M, Schneider D, Keefer MC, Clark R, Lai KK, Jacobson JM, Squires K, Bartlett JA, Powderly W. Itraconazole maintenance treatment for histoplasmosis in AIDS: a prospective, multicenter trial. J AIDS 1997; 16(2): 100-107.
12. Grant SM, Clissold SP. Fluconazole. A review of its pharmacodynamics and pharmacokinetics properties and therapeutic potential in superficial and systemic mycoses. Drugs 1990; 39: 877-916.
13. van der Horst CM. Saag MS. Cloud GA. Hamill RJ. Graybill JR. Sobel JD. Johnson PC. Tuazon CU. Kerkering T. Moskovitz BL. Powderly WG. Dismukes WE. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. New Engl J Med 1997; 337(1): 15-21.
14. Jacobson MA, Hanks DK, Ferrell LD. Fatal acute hepatic necrosis due to fluconazole. Am J Med 1994; 96(2): 188-90.
15. Somchit N, Hassim SM, Samsudin SH. Itraconazole-and fluconazole-induced toxicity in rat hepatocytes: a comparative in vitro study. Hum Exp Toxicol 2002; 21(1): 43-48.
16. Pekarthy J, Albert JS, Lansing A, Lieberman I. Function and control of liver alkaline phosphatase. J Biol Chem 1972; 247: 1767-74.
17. Van Cutsem J, Van Gerven F, Van de Ven MA, Borgers M, Janssen, PAJ. Itraconazole, a new triazole that is orally active in aspergillosis. Antimicrob Agents Chemother 1984; 26(4): 527-34.
18. Rodriquez RJ, Acosta D Jr. Inhibition of mitochondrial function in isolated rate liver mitochondria by azole antifungals. J Biochem Toxicol 1996; 11: 127-31.
19. Rodriquez RJ, Acosta D Jr. N-Deacetyl ketoconazole-induced hepatotoxicity in a primary culture system of rat hepatocytes. Toxicology 1997; 117: 123-31.
20. Rodriquez RJ, Acosta D Jr. Metabolism of ketoconazole and deacetylated ketoconazole by rat hepatic microsomes and flavin-containing monooxygenase. Drug Metab. Dispos 1997; 25: 727-77.
21. Rodriquez RJ, Proteau PJ, Marquez BL, Hetherington CL, Acosta D Jr. Flavin-ontaining monooxygenase-mediated metabolism of JV-deacetyl ketoconazole by rat hepatic microsomes. Drug Metab Dispos 1999; 27: 880-86.
22. Martin MV. The use of fluconazole and itraconazole in the treatment of Candida albicans infections: a review. J Antimicrob Chemother 1999; 44(4): 429-37.
23. Menon T, Umamaheswari K, Kumarasamy N, Solomon S, Thyagarajah SP. Efficacy of fluconazole and itraconazole in the treatment of oral candidiasis in HIV patients. Acta Trop 2001; 80: 151-54.
24. Chotmongkol V, Sukeepaisarncharoen W. Maintenance therapy with itraconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. J Med Assoc Thai 1997; 80(12): 767-70
25. Hecht FM, Wheat J, Korzun AH, Hafner R, Skahan KJ, Larsen R, Limjoco MT, Simpson M, Schneider D, Keefer MC, Clark R, Lai KK, Jacobson JM, Squires K, Bartlett JA, Powderly W. Itraconazole maintenance treatment for histoplasmosis in AIDS: a prospective, multicenter trial. J AIDS Hum Retrovirol 1997; 16(2): 100-107.